

EXERCISE OF WARRANTS OF SERIES TO3

EXERCISE PERIOD: 4 JUNE- 18 JUNE 2025

IMPORTANT INFORMATION

This information document has been prepared by Curasight A/S ("Curasight" or the "Company"). The reader is asked to read the prospectus published by Curasight on 12 September 2024, in connection with the Company's rights issue, for a description of the risks associated with an investment in the Company. The prospectus is available for download on the Company's website (www.curasight.com).

Curasight A/S

Curasight A/S ("Curasight") is a pioneering company developing an innovative imaging and therapeutic platform based on the urokinase-type plasminogen activator receptor (uPAR). This cutting-edge technology effectively minimizes radiation exposure to healthy tissues by combining targeted uTREAT® radiation therapy with precise uTRACE® diagnostics. Curasight has successfully completed or is currently conducting multiple investigator-initiated phase II clinical trials. The company is currently engaged in a phase II trial for prostate cancer as part of a global partnership with Curium, the world's leading radiopharmaceutical company. Additionally, Curasight is committed to advancing data generation for both uTRACE® and uTREAT® across various cancers, including prostate cancer, bladder cancer, glioblastoma (brain cancer), neuroendocrine tumors (NET), head and neck cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer.

Through the exercise of warrant of series TO3, Curasight can receive proceeds at a maximum of approximately DKK 28.6 million.

THE OFFER IN BRIEF

Exercise period:	4 June – 18 June 2025.
Exercise price:	DKK 15.55 per share.
Last day of trading in TO3:	16 June 2025.
Number of outstanding shares prior to warrant exercise:	45,864,010 shares.
Issue volume:	If warrants of series TO3 are fully exercised, approximately DKK 28.6 million will be added to the Company before issue costs.
ISIN-code for TO3:	DK0063183397.

TERMS IN SHORT

There are 1,841,907 issued warrants of series TO3. Holders of warrants of series TO3 have the right to subscribe for one (1) new share in Curasight A/S ("Curasight") at a price of DKK 15.55 per share for each warrant. Subscription with the support of warrants of series TO3 can take place during the period from and including 4 June 2025 to and including 18 June 2025. Subscription must take place by simultaneous cash payment no later than on 18 June 2025.

As a warrant holder, you need to decide whether to accept the offer. This is how you exercise your warrants of series TO3:

In order for your warrants not to expire worthless, you are required to subscribe for new shares, supported by warrants, by 18 June 2025 at the latest or sell your warrants by 16 June 2025 at the latest. All warrant holders should consult with their bank to confirm the final subscription date to ensure the opportunity is not missed. Subscription applications should be submitted directly through each respective bank.

You can have your warrants registered in the following way:

In a securities depository in a bank or with another administrator (for example, Avanza or Nordnet), in an investment savings account (ISK) or a capital insurance (KF). Your warrants are then trustee-registered.

Subscription and payment of new shares, with the support of warrants, must be made to the respective bank or other administrator where the warrants are registered. Subscription and payment shall be made in accordance with the instructions provided by each such bank or trustee. Usually the bank/custodian sends out a digital notice to the account holder, otherwise it is generally sufficient to log in to the securities depository from the first day of the exercise period to receive instructions on how to use warrants to subscribe for new shares. Please contact your bank or trustee if you cannot find these instructions. Note that banks and other administrators may set different time limits for subscription, therefore it is recommended that you contact your bank/administrator early in the usage period to obtain information about subscription and payment. Subscribed and paid shares may be registered in your securities depository as "interim shares" or "MIDL"

NOTE - In order for your warrants not to expire worthless, it is required that you actively subscribe for shares no later than 18 June 2025 or sell your warrants no later than 16 June 2025.

For any questions regarding warrants of series TO3, please contact Sedermera. Sedermera act as financial advisor for Curasight in connection with warrant exercise. DLA Piper Denmark Law Firm P/S acts as legal adviser. Danske Bank acts as settlement agent.

Sedermera Corporate Finance AB

Phone: +46 (0)40-615 14 10

E-mail: cf@sedermera.se

Danske Bank

E-mail: prospekter@danskebank.dk

Important dates for warrants of series TO3

